News & insights

Stay up to date with our latest products, technologies and company news, and meet our teams at upcoming events. We also share insights from consumer testing, scientific data and market trends across a broad range of application areas.

NordicCan Secures Two Patents issued by the Canadian Intellectual Property Office for the Administration of Cannabinoids through Oral Dosage Formats

NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, announced that the Canadian Intellectual Property Office has issued patent numbers CA 3,031,530 and CA 3,035,400 covering the use of cannabinoids within...

2021-03-10

Health Canada Grants Cannabis Research License to NordicCan

VEJLE, Denmark—March 7, 2021—NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, has obtained approval a Research License from Health Canada under the Cannabis Act. The Research License is a key...

2021-03-10

NordicCan Secures Two New US Patents for the Administration of Cannabinoids through Oral Dosage Formats

VEJLE, Denmark—March 5, 2021—NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, today announced that the United States Patent and Trademark Office (USPTO) has issued it two patents: U.S. Patent No....

2021-01-08

MedCan Pharma changes name to NordicCan

Full Contract Development and Manufacturing Organization will continue to specialize in innovative cannabinoid solutions for the B2B market MedCan Pharma A/S announced today the launch of a new corporate name and brand identity. The organization will now be known...

2019-07-10

Exploring the potential of the cannabis business

The global market for medicinal use of cannabis is expected to grow to a multi-billion dollar market over the coming years. This is primarily due to the cannabis legislation currently being under review or already changing in many countries...

2019-07-01

Fertin Pharma’s parent company acquires NordicCan – allowing entry into fast-growing market for cannabinoid products

Claudio Bidco A/S (the “Parent Company”), the parent company of Fertin Pharma A/S (“Fertin Pharma”) has signed and closed the acquisition of NordicCan A/S (“NordicCan”), a research organisation focusing on developing innovative products containing cannabinoids with a primary focus...

2019-07-01

Fertin Pharma acquires Tab Labs – provides the combined group a unique CDMO position in the North American dietary supplement market

Fertin Pharma A/S (“Fertin Pharma”) has signed and closed the acquisition of Tab Labs Inc. (“Tab Labs”), a leader in compressed gum and mints / lozenges and one of the largest contracts tableting companies in North America servicing customers...

Cookie	Type	Duration	Description
cookielawinfo-checkbox-necessary	0	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
viewed_cookie_policy	0	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Type	Duration	Description
cookielawinfo-checkbox-necessary	0	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
viewed_cookie_policy	0	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.